Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss

TRANSFUSION,  Volume 56, November 2016

 

Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss

 

Ugo Salvadori, 1 Marco Sandri, 2 Cristina Melli, 3 Francesca Polese, 4 Maria Simeoni, Stefano Capelli, 6 and Ahmad Al-Khaffaf1

 

From the 1Immunohaematology and Transfusion Service, Bozen/Bolzano Hospital, and the 2Centre for Biomedicine, European Academy Bozen/Bolzano (EURAC), Bozen/Bolzano, Italy; the 3Transfusion Medicine Department, Udine University Hospital, Udine, Italy; the 4Immunohaematology and Transfusion Service, Mestre Hospital, Mestre, Venezia, Italy; the 5Transfusion Service, San Dona di Piave Hospital, San Dona di Piave, Italy; and the 6Transfusion Service, Belluno Hospital, Belluno, Italy

 

Abstract

 

Background

The aim of this study was to evaluate the effectiveness of ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA) secondary to gastrointestinal chronic blood loss (CBL), who received chronic transfusion support. 

 

Study design and Methods

We retrospectively evaluated 38 patients with IDA (hemoglobin [Hb] < 10 g/dL and ferritin < 12 ng/mL or transferrin saturation [TSAT] < 16%) refractory or intolerant to oral iron therapy that necessitated transfusion support in the previous 12 months. They were treated with FCM (500-2500 mg). The primary endpoint was to evaluate the reduction of transfusion requirements (red blood cell [RBC] units) after FCM treatment.

 

Results

The median age of the cohort was 78 years, with a male:female ratio of 22:16. Before FCM treatment a median of 6 RBC units had been transfused. At the treatment (T0) the median value of Hb was 8.7 g/dL, the TSAT 6%, and ferritin 12 ng/mL. The median FCM dose was 1000 mg. At 5 weeks from T0 the median Hb level was 11 g/dL, with a median increase of 2.4 g/dL. With a median follow-up of 326 days, the median transfusion requirement was 0 RBC units, significantly lower than before T0 (p < 0.001). Overall 17 patients still necessitated transfusion support. Twenty-three patients needed retreatment with FCM for recurrence of IDA: 10 of them obtained a response again. The percentage of transfusion-independent patients at median follow-up was equal to 52%.

 

Conclusion

In patients with IDA secondary to CBL, FCM significantly reduces the need of transfusions and achieves transfusion independence in half of the cases.

 

(Reference link : http://onlinelibrary.wiley.com/doi/10.1111/trf.13794/abstract)